AbbVie Inc. has a long leadership position in autoimmune diseases due to its top-selling TNF inhibitor Humira (adalimumab) and continues to build on its legacy in inflammatory bowel disease (IBD) via the newer blockbusters Skyrizi (risankizumab) and Rinvoq (upadacitinib). Approved in the US for ulcerative colitis in March, the company now has the data it needs to seek approvals for Rinvoq in Crohn’s disease while it awaits a US Food and Drug Administration decision in June that would make Crohn’s the first IBD indication for Skyrizi.
AbbVie reported top-line results on 11 May from the Phase III U-ENDURE clinical trial testing the JAK1 inhibitor Rinvoq versus...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)